Loading
A phase 3 trial of Synthetic hypericin in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by Soligenix, recorded as terminated on the registry.
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL is a phase 3 interventional study registered as NCT06470451 by Soligenix, with 70 participants recorded, started 2025-01-07 and due to reach its primary completion in 2026-05-22. Interventions recorded: Hypericin, Placebo. Conditions recorded: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma.
Linked to the drug Synthetic hypericin because the registry names it among its interventions and Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.
Shares Synthetic hypericin, Soligenix, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Synthetic hypericin, Soligenix, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.